Pancreatic Cancer Research

ResearcherUniversity of Alabama at BirminghamActive in the last 2 years

Martin J. Heslin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9932-2362; OpenAlex author ID A5071825465. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
41
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 4 papers · 2023: 3 papers · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 18

  1. Biology vs Barriers: The Impact of Socioeconomic Disadvantage on Overall Survival in Pancreatic Cancer Despite Guideline-Concordant Treatment. Last author DOI 10.1097/xcs.0000000000001754↗
  2. Disparities in access to surgical resection in patients with pancreatic cancer - a systematic review. Co-author DOI 10.1016/j.gassur.2025.102037↗
  3. Neoadjuvant Therapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: A Systemic Review and Meta-Analysis. Co-author DOI 10.1016/j.jss.2025.04.042↗
  4. Corrigendum to 'Neoadjuvant Therapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: A Systemic Review and Meta-analysis' Jou… Co-author DOI 10.1016/j.jss.2025.10.015↗
  5. Association between Rural Residence and Processes of Care in Pancreatic Cancer Treatment. Co-author DOI 10.1007/s11605-023-05764-z↗
  6. Palliative Therapies in Metastatic Pancreatic Cancer: Does Medicaid Expansion Make a Difference? Co-author DOI 10.1245/s10434-022-12563-4↗
  7. ASO Author Reflections: Disparities in Receipt of Palliative Therapies for Pancreatic Cancer: Did Medicaid Expansion Help? Co-author DOI 10.1245/s10434-022-12638-2↗
  8. Fragmentation of Care in Pancreatic Cancer: Effects on Receipt of Care and Survival. First author DOI 10.1007/s11605-022-05478-8↗
  9. Detection of mitochondrial DNA mutations in circulating mitochondria-originated extracellular vesicles for potential diagnostic applications in pancreatic aden… Co-author DOI 10.1038/s41598-022-22006-5↗
  10. Association of Medicaid Expansion with Pancreatic Cancer Treatment and Outcomes: Evidence from the National Cancer Database. Co-author DOI 10.1245/s10434-021-10709-4↗
  11. Disparities in Access to Oncologic Care in Pancreatic Cancer: A Systematic Review. Co-author DOI 10.1245/s10434-021-11258-6↗
  12. Healthcare disparities in outcomes of patients with resectable pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2018.12.007↗
  13. Increased pancreatic cancer survival with greater lymph node retrieval in the National Cancer Data Base. Last author DOI 10.1016/j.amjsurg.2017.06.036↗
  14. Chemoproteomic Screening of Covalent Ligands Reveals UBA5 As a Novel Pancreatic Cancer Target. Co-author DOI 10.1021/acschembio.7b00020↗
  15. RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. Co-author DOI 10.1016/j.molonc.2016.05.004↗
  16. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. Co-author DOI 10.1007/s12029-015-9702-7↗
  17. Pancreatic adenocarcinoma: a pilot study of quantitative perfusion and diffusion-weighted breath-hold magnetic resonance imaging. Co-author DOI 10.1007/s00261-014-0107-z↗
  18. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2011.263↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Annabelle L. Fonseca · 10 shared papers, 2022–2026 · strength 2.22
  2. Hamza Khan · 6 shared papers, 2022–2025 · strength 1.23
  3. Fabian Mc. Johnston · 5 shared papers, 2022–2023 · strength 0.96
  4. Sushanth Reddy · 4 shared papers, 2017–2025 · strength 0.73
  5. Krisha Amin · 3 shared papers, 2023–2026 · strength 0.72
  6. John Bart Rose · 2 shared papers, 2025 · strength 0.54
  7. Michelle M. Holland · 2 shared papers, 2025 · strength 0.54
  8. Chandler A. Annesi · 2 shared papers, 2025 · strength 0.54
  9. Vikas Dudeja · 2 shared papers, 2025 · strength 0.54
  10. Michelle M. Holland · 2 shared papers, 2025–2026 · strength 0.53
  11. Manish Tripathi · 2 shared papers, 2023–2026 · strength 0.47
  12. Carlo M. Contreras · 3 shared papers, 2017–2019 · strength 0.26
  13. Seema Singh · 1 shared paper, 2022 · strength 0.16
  14. Hop S. Tran Cao · 1 shared paper, 2022 · strength 0.16
  15. Santanu Dasgupta · 1 shared paper, 2022 · strength 0.16
  16. Moh'd M. Khushman · 1 shared paper, 2022 · strength 0.16
  17. Kunwar Somesh Vikramdeo · 1 shared paper, 2022 · strength 0.16
  18. Shashi Anand · 1 shared paper, 2022 · strength 0.16
  19. Mohammad Aslam Khan · 1 shared paper, 2022 · strength 0.16
  20. Ajay P. Singh · 1 shared paper, 2022 · strength 0.16
  21. Ching-Wei David Tzeng · 1 shared paper, 2022 · strength 0.16
  22. John D. Christein · 3 shared papers, 2014–2016 · strength 0.14
  23. James A. Posey · 3 shared papers, 2014–2016 · strength 0.14
  24. Selwyn Maurice Vickers · 2 shared papers, 2016–2017 · strength 0.13
  25. Omeed Moaven · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.